BACKGROUND: This study estimated temporal trends of metabolic control over 12 years in a national cohort of childhood-onset type 1 diabetes. SUBJECTS AND METHODS: Data from the prospective childhood-onset diabetes register, which included 886 case subjects from 0 to 17.99 years of age at diagnosis and at least 1 year of follow-up until the age of 22.99 years, were analyzed using multivariable linear and logistic regression models in the observational period between 2000 and 2011. RESULTS: Hemoglobin A1c (HbA1c) significantly decreased over 12 years, from 78 mmol/mol (interquartile range [IQR], 68-88 mmol/mol) (9.26% [IQR, 8.41-10.24%]) in the year 2000 to 61 mmol/mol (IQR, 55-67 mmol/mol) (7.75% [IQR, 7.20-8.30%]) in the year 2011 (P<0.001). HbA1c was significantly associated with age, treatment modality, and duration of diabetes (P<0.001), with females having on average 1.02% higher HbA1c (P=0.01; 95% confidence interval [CI] 1.005-1.035). The overall use of insulin pumps was 74%. The incidence rate of severe acute complications was low: 1.07 per 100 patient-years for severe diabetic ketoacidosis (95% CI 0.81-1.40) and 1.21 per 100 patient-years for severe (requiring intravenous or intramuscular therapy) hypoglycemia (95% CI 0.81-1.40). CONCLUSIONS: The metabolic control of the entire nationwide pediatric type 1 diabetes population significantly improved during the 12-year observational period with a low rate of severe acute complications events. The improvement was associated with the treatment modality. Additional efforts and solutions are necessary to further improve metabolic control and the quality of life of young people with type 1 diabetes.
BACKGROUND: This study estimated temporal trends of metabolic control over 12 years in a national cohort of childhood-onset type 1 diabetes. SUBJECTS AND METHODS: Data from the prospective childhood-onset diabetes register, which included 886 case subjects from 0 to 17.99 years of age at diagnosis and at least 1 year of follow-up until the age of 22.99 years, were analyzed using multivariable linear and logistic regression models in the observational period between 2000 and 2011. RESULTS: Hemoglobin A1c (HbA1c) significantly decreased over 12 years, from 78 mmol/mol (interquartile range [IQR], 68-88 mmol/mol) (9.26% [IQR, 8.41-10.24%]) in the year 2000 to 61 mmol/mol (IQR, 55-67 mmol/mol) (7.75% [IQR, 7.20-8.30%]) in the year 2011 (P<0.001). HbA1c was significantly associated with age, treatment modality, and duration of diabetes (P<0.001), with females having on average 1.02% higher HbA1c (P=0.01; 95% confidence interval [CI] 1.005-1.035). The overall use of insulin pumps was 74%. The incidence rate of severe acute complications was low: 1.07 per 100 patient-years for severe diabetic ketoacidosis (95% CI 0.81-1.40) and 1.21 per 100 patient-years for severe (requiring intravenous or intramuscular therapy) hypoglycemia (95% CI 0.81-1.40). CONCLUSIONS: The metabolic control of the entire nationwide pediatric type 1 diabetes population significantly improved during the 12-year observational period with a low rate of severe acute complications events. The improvement was associated with the treatment modality. Additional efforts and solutions are necessary to further improve metabolic control and the quality of life of young people with type 1 diabetes.
Authors: Katarina Eeg-Olofsson; Jan Cederholm; Peter M Nilsson; Soffia Gudbjörnsdóttir; Björn Eliasson Journal: Diabetes Care Date: 2007-03 Impact factor: 19.112
Authors: T Danne; T Battelino; P Jarosz-Chobot; O Kordonouri; E Pánkowska; J Ludvigsson; E Schober; E Kaprio; T Saukkonen; M Nicolino; N Tubiana-Rufi; C Klinkert; H Haberland; A Vazeou; L Madacsy; D Zangen; V Cherubini; I Rabbone; S Toni; C de Beaufort; W Bakker-van Waarde; N van den Berg; I Volkov; R Barrio; R Hanas; U Zumsteg; B Kuhlmann; C Aebi; U Schumacher; S Gschwend; P Hindmarsh; M Torres; N Shehadeh; M Phillip Journal: Diabetologia Date: 2008-07-01 Impact factor: 10.122
Authors: Carine E de Beaufort; Peter G F Swift; Chas T Skinner; Henk J Aanstoot; Jan Aman; Fergus Cameron; Pedro Martul; Francesco Chiarelli; Dennis Daneman; Thomas Danne; Harry Dorchy; Hilary Hoey; Eero A Kaprio; Francine Kaufman; Mirjana Kocova; Henrik B Mortensen; Pal R Njølstad; Moshe Phillip; Kenneth J Robertson; Eugen J Schoenle; Tatsuhiko Urakami; Maurizio Vanelli Journal: Diabetes Care Date: 2007-05-31 Impact factor: 19.112
Authors: Paolo Pozzilli; Tadej Battelino; Thomas Danne; Roman Hovorka; Przemyslawa Jarosz-Chobot; Eric Renard Journal: Diabetes Metab Res Rev Date: 2015-06-22 Impact factor: 4.876
Authors: Priya Prahalad; Dessi P Zaharieva; Ananta Addala; Christin New; David Scheinker; Manisha Desai; Korey K Hood; David M Maahs Journal: Front Endocrinol (Lausanne) Date: 2020-07-09 Impact factor: 5.555